Related Experiment Videos
I-123 whole body scanning: case report and discussion
Herbert A Klein1, Kenneth J DiSibio, Diane Sims
1Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15240, USA. herbert.klein@med.va.gov
Clinical Nuclear Medicine
|April 14, 2005
Summary
Iodine-123 (I-123) whole body imaging shows comparable accuracy to Iodine-131 (I-131) for differentiated thyroid carcinoma, offering reduced radiation exposure. This case suggests I-123 may be superior for detecting metastases.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiopharmaceuticals
Background:
- Differentiated thyroid carcinoma management involves whole body imaging to detect metastases.
- Traditional Iodine-131 (I-131) imaging raises concerns about radiation-induced stunning.
- Interest is growing in Iodine-123 (I-123) for diagnostic imaging due to its favorable properties.
Observation:
- A 43-year-old man with papillary thyroid carcinoma underwent post-thyroidectomy imaging with I-123.
- I-123 imaging at 24 and 48 hours revealed multiple regional metastases.
- Subsequent I-131 therapeutic scans showed less distinct metastatic foci, with negative imaging a year later indicating treatment success.
Findings:
- I-123 offers advantages of favorable gamma-ray energy and lower radiation dose to thyroid tissue and the body.
- Despite a shorter half-life, adequate doses of I-123 allow for practical 48-hour delayed imaging.
- The presented case demonstrated superior lesion detection with I-123 compared to I-131 post-therapy scans, challenging the "gold standard" status of I-131.
Implications:
- I-123 whole body imaging is a viable and potentially more accurate diagnostic tool for differentiated thyroid carcinoma.
- Careful consideration of technical factors in comparative studies is crucial for accurate assessment of imaging modalities.
- I-123 may offer a better balance between diagnostic efficacy and patient safety in follow-up imaging.